Citing blood clot risks, CDC advisers recommend mRNA pandemic vaccines over J&J shot

Ever since federal officials briefly halted Johnson & Johnson's COVID-19 vaccine rollout this spring, the shot has seen limited use in the U.S. Now, the program is hitting another major setback.

Citing new data on the risk of potentially deadly blood clots associated with the J&J shot, Centers for Disease Control and Prevention (CDC) vaccine advisers have recommended use of mRNA shots from Pfizer and Moderna over J&J's vaccine, The Washington Post reports.